Raymond N. DuBois was named director of MUSC Hollings Cancer Center effective Aug. 17.
Stephen Nimer: Cancer patients are coming in for treatment, Florida’s COVID-19 spike notwithstanding
“Our chemotherapy and radiation therapy volumes have been very robust. Probably because of the NCI designation, we are seeing significantly more patients than last year,” Stephen D. Nimer, director of Sylvester Comprehensive Cancer Center, said to The Cancer Letter. “Compared to last year, we seem to be up about 15%. We’ve been growing by about 8% to 9% for quite some years. This year is even more.”
Jason M. Hafron, director of research at the Michigan Institute of Urology, was taken aback by the results of a study he was conducting: the vast majority of patients with prostate cancer who need regular injections to suppress their testosterone levels didn't get treated on time.
In early March, when Giuseppe Curigliano, an oncologist in Milan, first spoke with The Cancer Letter about COVID-19, the situation in Italy was “like being in a war zone.”
As cases of COVID-19 surge in Florida, Lucio Gordan, managing physician and president of Florida Cancer Specialists and Research Institute, is working to increase the role of telehealth.
Last time Ruben Mesa spoke with The Cancer Letter, COVID-19 was under control in San Antonio and the environs—or so it seemed.
By making lung cancer screening available to a larger population, the new guideline from the U.S. Preventive Services Task Force could save an additional 120 lives per 100,000 Americans, said Michael J. Barry, a member of the Task Force, and a professor of medicine at Harvard Medical School.
Any way you look at it, Northwell Health, New York’s largest health system, took a massive hit from COVID-19.
“It just dawned upon us, ‘Hey, we know how to block inflammation,’” recalls Louis Staudt, chief of NCI’s Lymphoid Malignancies Branch and director of the Center for Cancer Genomics.
If you look at attendance, COVID-19 didn’t derail ASCO20.
